BUKWANG PHARMACEUTICAL, Routine OCI Group Status Disclosure... Stable Financial Structure, No Material Changes
BUKWANG PHARMACEUTICAL, as a member of OCI business group, discloses financial status for FY2025: total assets 468.0B KRW, total liabilities 127.6B KRW, total equity 340.4B KRW, debt ratio 37.5%, indicating stable financial structure.
FY2025 operating performance: revenue 167.3B KRW, operating profit 16.1B KRW, net income 14.4B KRW, showing sound profitability.
Major shareholder is OCI Holdings Co., Ltd. holding 16,878,791 shares (17.11%), other shareholders hold 81,785,880 shares (82.89%). No changes in related party shareholding.
Intra-group transactions: received 18M KRW for management services from OCI Holdings, holds 100% of BUKWANG Medica, and other minor internal transactions.
Board resolutions including quarterly dividend approval in Oct 2025 and bio fund investment (Quad) in Feb 2026 are within routine management scope.
[AI Comprehensive Analysis]This disclosure is a routine periodic report of a large business group affiliate, containing no direct value-impacting events such as new capital raising, share buyback/cancellation, or dividend increases. Therefore, it is expected to have a neutral impact on the stock price. While financial health and operations are stable, the absence of growth catalysts may be considered a risk factor.
KOSPI Filing Information
Filing: Large Enterprise Group Status Disclosure [Annual And First Quarter Use (Individual Company)]